Stock Events

Stock Events

Hoth Therapeutics 

$0.7639
93
-$0.01-1.28% Friday 19:59

Statistics

Day High
0.7644
Day Low
0.7639
52W High
2.45
52W Low
0.4894
Volume
4,753
Avg. Volume
-
Mkt Cap
19.02M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2DecExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.31
-0.25
-0.2
-0.14
Expected EPS
-0.1541
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-12.47MNet Income

Analyst Ratings

5.00Average Price Target
The highest estimate is 5.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap55.09B
Moderna is a leader in mRNA technology, which competes in the biotech space for developing treatments similar to Hoth Therapeutics' focus on novel therapeutics.
BioNTech
BNTX
Mkt Cap25.64B
BioNTech competes with Hoth in the development of new therapies, including in the immunology and oncology sectors, leveraging mRNA technology.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is involved in the discovery, development, and commercialization of medicines for serious diseases, directly competing with Hoth's therapeutic development efforts.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals focuses on creating new treatments for cystic fibrosis and other serious diseases, competing with Hoth's disease target areas.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a biopharmaceutical company that develops and markets drugs to address high unmet medical needs, overlapping with Hoth's mission.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotech firm focusing on human therapeutics, with a broad portfolio that competes across several of Hoth Therapeutics' areas of interest.
Biogen
BIIB
Mkt Cap32.28B
Biogen develops therapies for neurological and neurodegenerative diseases, competing with Hoth's focus on novel therapeutic approaches.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie operates in the same biopharmaceutical field, developing drugs for conditions that Hoth Therapeutics also targets, such as autoimmune diseases.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global pharmaceutical company with a wide range of products that compete with Hoth Therapeutics in the development of new drugs and treatments.
Novartis
NVS
Mkt Cap292.35B
Novartis is a global healthcare company that operates in various therapeutic areas, including those targeted by Hoth Therapeutics, making it a direct competitor.

About

Rocket One Inc is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic AI chip technology designed for radiation-tolerant, energy-constrained environments such as low-Earth orbit, deep-space platforms, and defense systems. The company also intends to pursue opportunities related to nano-launch systems and nanosatellite deployment. In addition, its biotechnology operations, conducted through a wholly owned subsidiary, include development programs such as HT-001, HT-KIT, HT-ALZ, and a GDNF-based metabolic program.
Show more...
CEO
Robbie Knie
Employees
3
Country
United States
ISIN
US44148G1058

Listings

XNAS
US
RKTO
BOATS
BOATS
HOTH.BOATS

0 Comments

Share your thoughts

FAQ

What is Hoth Therapeutics stock price today?▼
The current price of HOTH is $0.76 USD — it has decreased by -1.28% in the past 24 hours. Watch Hoth Therapeutics stock price performance more closely on the chart.
What is Hoth Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Hoth Therapeutics stocks are traded under the ticker HOTH.
What is Hoth Therapeutics market cap?▼
Today Hoth Therapeutics has the market capitalization of 19.02M
When is the next Hoth Therapeutics earnings date?▼
Hoth Therapeutics is going to release the next earnings report on December 02, 2026.
What is Hoth Therapeutics revenue for the last year?▼
Hoth Therapeutics revenue for the last year amounts to 0 USD.
What is Hoth Therapeutics net income for the last year?▼
HOTH net income for the last year is -12.47M USD.
How many employees does Hoth Therapeutics have?▼
As of September 05, 2026, the company has 3 employees.
In which sector is Hoth Therapeutics located?▼
Hoth Therapeutics operates in the Technology sector.
When did Hoth Therapeutics complete a stock split?▼
The last stock split for Hoth Therapeutics was on October 26, 2022 with a ratio of 1:25.
Where is Hoth Therapeutics headquartered?▼
Hoth Therapeutics is headquartered in HOBOKEN, United States.